Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
INVO Fertility ( (IVF) ) has provided an announcement.
On October 6, 2025, an institutional investor in INVO Fertility, Inc. exercised its Additional Investment Right to acquire 200 shares of Series C-2 Convertible Preferred Stock for $200,000. This transaction resulted in an adjusted conversion price of $0.6643 per share and was conducted as a private offering under the Securities Act exemptions, impacting the company’s financial structure and shareholder equity.
The most recent analyst rating on (IVF) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.
Spark’s Take on IVF Stock
According to Spark, TipRanks’ AI Analyst, IVF is a Underperform.
The overall stock score is primarily impacted by poor financial performance and bearish technical indicators. The company’s significant operational losses and high leverage pose substantial risks. The negative P/E ratio and lack of dividend yield further weaken the valuation. Despite a positive corporate event, the overall outlook remains challenging.
To see Spark’s full report on IVF stock, click here.
More about INVO Fertility
Average Trading Volume: 1,528,572
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.61M
See more insights into IVF stock on TipRanks’ Stock Analysis page.